- Price
- $335.96
- Day
- -1.54%
- Mkt Cap
- $128.79B
- 52W Range
- $281.00 – $396.86
- Volume
- 2.54M
- Beta
- 0.78
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
Stryker tops Q2 estimates as sales regain momentum after a cyber disruption, but narrowed 2026 guidance weighs on shares, sending them down 7.8% in after-hours trading.
Read full article
Organic Sales Growth: 9% for Q2 2026, against a double-digit comparable in Q2 2025.Adjusted EPS: $3.69, up 17.9% year-over-year.Adjusted Gross Margin: 66%, 60 b
Read full article
Stryker NYSE: SYK reported 9% organic sales growth in the second quarter of 2026 and adjusted earnings per share growth of 17.9%, as the medical technology company continued recovering from a cybersecurity incident that disrupted operations earlier in the year.
Read full article
The medical technology company reported a profit of $1.28 billion and and said it has made progress in recovering from a March cyberattack.
Read full article
The headline numbers for Stryker (SYK) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Read full article
Stryker (SYK) came out with quarterly earnings of $3.69 per share, beating the Zacks Consensus Estimate of $3.46 per share. This compares to earnings of $3.13 per share a year ago.
Read full article
Stryker Corporation (SYK) Q2 2026 Earnings Call Transcript
Read full article
U.S. medical device maker Stryker on Thursday beat Wall Street estimates for second-quarter results, aided by strong demand for its implants and devices used in complex procedures ranging from spinal to orthopedic surgeries.
Read full article
Portage, Michigan, July 30, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) reported operating results for the second quarter of 2026:
Read full article
Medical product makers face Q2 margin pressure from tariffs and inflation even as demand stays strong. See which earnings reports could surprise.
Read full article
SYK heads into Q2 with robotic surgery momentum, deferred revenue recovery and strong procedure demand as investors watch for earnings and margin trends.
Read full article
Besides Wall Street's top-and-bottom-line estimates for Stryker (SYK), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2026.
Read full article